--- title: "Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day" type: "News" locale: "en" url: "https://longbridge.com/en/news/295449096.md" description: "Regeneron Pharmaceuticals (REGN) stock rose 3.02% to $808.05, outperforming competitors like Amgen and Moderna on a generally weak trading day. This marks the fifth consecutive daily gain for Regeneron, leaving it just 1.59% below its 52-week high of $821.11. Trading volume exceeded the 50-day average, indicating strong investor interest despite broader market declines in the S&P 500 and Dow Jones." datetime: "2026-08-10T20:44:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295449096.md) - [en](https://longbridge.com/en/news/295449096.md) - [zh-HK](https://longbridge.com/zh-HK/news/295449096.md) generator: "portal-rs" --- # Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Regeneron Pharmaceuticals Inc. (REGN) advanced 3.02% to $808.05 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.06% to 7,753.11 and Dow Jones Industrial Average falling 0.11% to 53,975.98. This was the stock's fifth consecutive day of gains. Regeneron Pharmaceuticals Inc. closed 1.59% short of its 52-week high of $821.11, which the company achieved on January 9th. The stock outperformed some of its competitors Monday, as Amgen Inc. (AMGN) rose 1.52% to $417.20, Moderna Inc. (MRNA) rose 1.08% to $59.81, and Gilead Sciences Inc. (GILD) fell 0.11% to $133.06. Trading volume (991,002) eclipsed its 50-day average volume of 962,464. Data source: Dow Jones Market Data, FactSet. Data compiled August 10, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 08-10-26 1644ET ### Related Stocks - [REGN.US](https://longbridge.com/en/quote/REGN.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) ## Related News & Research - [04:39 ETRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN](https://longbridge.com/en/news/296589805.md) - [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md) - [Regeneron says FDA approves Pasatru for adults with rare bone disorder FOP](https://longbridge.com/en/news/296387064.md) - [Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug](https://longbridge.com/en/news/296499413.md) - [12:50 ETREGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt](https://longbridge.com/en/news/295826897.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**